Evidence map›Paper›PMID 28157626›Full record

ArticleNuclear medicine and biology2017

Evaluation of [

Giuseppe Carlucci, Brandon Carney, Ahmad Sadique, Axel Vansteene, Jun Tang, Thomas Reiner

Abstract read
In one paragraph

Article in Nuclear medicine and biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Giuseppe CarlucciDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Brandon CarneyDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA; Department of Chemistry, Hunter College and PhD Program in Chemistry, The Graduate Center of the City University of New York, New York, NY 10018, USA.
Ahmad SadiqueDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Axel VansteeneDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Jun TangDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Thomas ReinerDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA; Weill Cornell Medical College, New York, NY, 10065, USA. Electronic address: reinert@mskcc.org.
Memorial Sloan Kettering Cancer Center · USCity University of New York · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Radioiodinated Multifunctional PARP1 Imaging Probes for Diagnosis and TherapyR01CA204441 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI PILLARSETTY, NAGAVARAKISHORE · 2016 to 2020
$2.9M
Bioorthogonal Strategies for Targeted PET Imaging Probe DevelopmentK25EB016673 · NIBIB · SLOAN-KETTERING INST CAN RESEARCH · PI REINER, THOMAS · 2013 to 2015
$525k
Development of Nuclear Auger Emitters for Targeted RadiotherapyR21CA191679 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI REINER, THOMAS, WEBER, WOLFGANG · 2015 to 2016
$187k
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA204441NCI NIH HHS R21 CA191679NIBIB NIH HHS K25 EB016673
6 · The paper itself

Abstract

rationaleAtaxia telangiectasia and Rad3-related (ATR) threonine serine kinase is one of the key elements in orchestrating the DNA damage response (DDR). As such, inhibition of ATR can amplify the effects of chemo- and radiation-therapy, and several ATR inhibitors (ATRi) have already undergone clinical testing in cancer. For more accurate patient selection, monitoring and staging, real-time in vivo imaging of ATR could be invaluable; the development of appropriate imaging agents has remained a major challenge.

methods3-amino-N-(4-[

results[

conclusions[

Indexed as

Fluorine RadioisotopesAnimalsAtaxia Telangiectasia Mutated ProteinsBrain NeoplasmsCell Line, TumorCell Transformation, NeoplasticHumansHydrophobic and Hydrophilic InteractionsMicePositron-Emission TomographyProtein Kinase InhibitorsPyrazinesRadioactive TracersRadiochemistrySulfonesTissue Distribution3-amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-carboxamideAtaxia Telangiectasia Mutated ProteinsATR protein, humanFluorine RadioisotopesProtein Kinase InhibitorsPyrazinesRadioactive TracersSulfones(18)FATRCell cyclePET imagingU251 mgVe-821

Identifiers

PMID28157626
PMCPMC5524211
OpenAlexW2578909204

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.